COPLAVIX

This brand name is authorized in Australia, Ecuador, Hong Kong, Mexico, Singapore, South Africa

Active ingredients

The drug COPLAVIX contains a combination of these active pharmaceutical ingredients (APIs):

1 Clopidogrel UNII 08I79HTP27 - CLOPIDOGREL BISULFATE

Clopidogrel is a prodrug, one of whose metabolites is an inhibitor of platelet aggregation. Clopidogrel must be metabolised by CYP450 enzymes to produce the active metabolite that inhibits platelet aggregation. Read about Clopidogrel

2 Acetylsalicylic acid UNII R16CO5Y76E - ASPIRIN

Acetylsalicylic acid combines significant advantages such as strong anti-pyretic, analgesic and anti-inflammatory action, that is the measure of comparison with all the newer NSAIDs. Read about Acetylsalicylic acid

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
COPLAVIX Film-coated tablet	Marketing Authorisation Holder	MPI, Generic

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
B01AC30	Combinations	B Blood and blood forming organs → B01 Antithrombotic agents → B01A Antithrombotic agents → B01AC Platelet aggregation inhibitors excl. heparin
Discover more medicines within B01AC30

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: AU	Pharmaceutical Benefits Scheme	Identifier(s): 9296G
Country: EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	Identifier(s): 943-MEE-0415
Country: HK	Department of Health Drug Office	Identifier(s): 59807
Country: MX	Comisión Federal para la Protección contra Riesgos Sanitarios	Identifier(s): 291M2009
Country: SG	Health Sciences Authority	Identifier(s): 13514P
Country: ZA	Health Products Regulatory Authority	Identifier(s): 44/8.2/0637, 44/8.2/0638